소포 변이 유두갑상샘암종의 면역조직화학염색 표지자들의 발현과 진단적 유용성
Availability of Immunohistochemistry in the Diagnosis of Follicular Variant of Papillary Thyroid Carcinoma
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background : Making the diagnosis of the follicular variant of papillary thyroid carcinoma (FVPTC) is often difficult, and there are no accurate immunohistochemical or molecular markers. The purpose of this study is to evaluate performing immunohistochemistry to make the diagnosis of FVPTC. Methods : A total of 249 thyroid lesions were studied. We made the tissue microarray, and we assessed the expression of HBME-1, galectin-3, CD56, and p63. Results : Galectin-3, HBME-1, and p63 were positive in 79.7%, 79.7%, and 15.9% of the FVPTC, respectively. These immunohistochemical features of FVPTC were between those of classic papillary thyroid carcinoma (CPTC) and those of non-PTC. The CD56 expression was positive in 75.4% of the FVPTC, which is much higher than that of the CPTC (28.3%), and even higher than that of the non-PTC lesions (60%). Comparing FVPTC with CPTC, the expression of galectin-3 was significantly higher and the expression of CD56 was significantly lower in the CPTCs. Comparing the FVPTC with follicular carcinoma (FC), the expression of all the markers was significantly higher in the FVPTC. Comparing PTC with FC, the expression of CD56 was lower and the expressions of the other markers were higher in the PTCs. Conclusions : Galectin-3, HBME-1, and p63 can help make the diagnosis of FVPTC, and a cocktail of these markers can be even more useful. But CD56 is not thought to be useful to make the diagnosis of FVPTC.
Abstract
Background : Making the diagnosis of the follicular variant of papillary thyroid carcinoma (FVPTC) is often difficult, and there are no accurate immunohistochemical or molecular markers. The purpose of this study is to evaluate performing immunohistochemistry to make the diagnosis of FVPTC. Methods : A total of 249 thyroid lesions were studied. We made the tissue microarray, and we assessed the expression of HBME-1, galectin-3, CD56, and p63. Results : Galectin-3, HBME-1, and p63 were positive in 79.7%, 79.7%, and 15.9% of the FVPTC, respectively. These immunohistochemical features of FVPTC were between those of classic papillary thyroid carcinoma (CPTC) and those of non-PTC. The CD56 expression was positive in 75.4% of the FVPTC, which is much higher than that of the CPTC (28.3%), and even higher than that of the non-PTC lesions (60%). Comparing FVPTC with CPTC, the expression of galectin-3 was significantly higher and the expression of CD56 was significantly lower in the CPTCs. Comparing the FVPTC with follicular carcinoma (FC), the expression of all the markers was significantly higher in the FVPTC. Comparing PTC with FC, the expression of CD56 was lower and the expressions of the other markers were higher in the PTCs. Conclusions : Galectin-3, HBME-1, and p63 can help make the diagnosis of FVPTC, and a cocktail of these markers can be even more useful. But CD56 is not thought to be useful to make the diagnosis of FVPTC.
참고문헌 (29)
- DeLellis RA, "WHO classification of tumours. Pathology and genetics of tumours of endocrine organs" (2004), IARC Press
- Rosai J, "Atlas of Tumor Pathology. Tumors of the thyroid gland" (1992), Armed Forces Institute of Pathology
- Zidan J, "Pure versus follicular variant of papillary thyroid carcinoma:clinical features,prognostic factors,treatment,and survival", Cancer, 97, pp.1181~1185 (2003)
- Chan JK, "Strict criteria should be applied in the diagnosis of encapsulated follicular variant of papillary thyroid carcinoma", Am J Clin Pathol, 117, pp.16~18 (2002)
- Lloyd RV, "Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma", Am J Surg Pathol, 28, pp.1336~1340 (2004)
- Renshaw AA, "Why there is the tendency to"overdiagnose"the follicular variant of papillary thyroid carcinoma", Am J Clin Pathol, 117, pp.19~21 (2002)
- Prasad ML, "Galectin-3,fibronectin-1,CITED-1,HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors", Mod Pathol, 18, pp.48~57 (2005)
- Young Joo Park, "Diagnostic Value of Galectin-3, HBME-1, Cytokeratin 19, HighMolecular Weight Cytokeratin, Cyclin D1 and p27kip1 in the DifferentialDiagnosis of Thyroid Nodules", Journal of Korean Medical Science, 22(4), pp.621~628 (2007), 대한의학회
- El Demellawy D, "Application of CD56,P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid", Diagn Pathol, 3, pp.5~ (2008)
- Krzeslak A, "Galectin-3 as a multifunctional protein", Cell Mol Biol Lett, 9, pp.305~328 (2004)
- de Matos PS, ""Usefulness of HBME-1,cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy", Histopathology, 47, pp.391~401 (2005)
- Herrmann ME, "Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions", Arch Pathol Lab Med, 126, pp.710~713 (2002)
- 박문일, "갑상샘종양의 감별진단에서 Galectin-3, Cytokeratin 19, p53, Ki-67의 유용성", The Korean Journal of Pathology, 40(2), pp.86~92 (2006), 대한병리학회
- Sheibani K, ""Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma.Hum", Pathol, 23, pp.107~116 (1992)
- Miettinen M, "Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours.Preferential reactivity with malignant tumours", Virchows Arch, 429, pp.213~219 (1996)
- Cavallaro U, "N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling", Nat Cell Biol, 3, pp.650~657 (2001)
- Prag S, "NCAM regulates cell motility", J Cell Sci, 115, pp.283~292 (2002)
- Fogar P, "Neural cell adhesion molecule(N-CAM)in gastrointestinal neoplasias", Anticancer Res, 17, pp.1227~1230 (1997)
- Zeromski J, "Protein and mRNA expres sion of CD56", N-CAM on follicular epithelial cells of the human thyroid, 1999, pp.12, 23~30
- Levrero M, "The p53", p63, J Cell Sci, pp.2000, 113[DOI]
- Preto A, "P63 expression in papillary and anaplastic carcinomas of the thyroid gland:lack of an oncogenetic role in tumorigenesis and progression", Pathol Res Pract, 198, pp.449~454 (2002)
- Kim YW, "Expression of the GLUT1 glucose transporter,p63 and p53 in thyroid carcinomas", Pathol Res Pract, 202, pp.759~765 (2006)
- Unger P, "Expression of p63 in papillary thyroid carcinoma and in Hashimoto’s thyroiditis:a pathobiologic link?", Hum Pathol, 34, pp.764~769 (2003)
- Burstein DE, "Immunohistochemical detection of p53 homolog p63 in solid cell nests, papillary thyroid carcinoma, and hashimoto’s thyroiditis: a stem cell hypothesis of papillary carcinoma oncogenesis", Hum Pathol, 35, pp.465~473 (2004)
- Baloch ZW, "lesions of the thyroid:the bane of the pathologist", Am J Clin Pathol, 117, pp.143~150 (2002)
- Burningham AR, "Papillary and follicular variant of papillary carcinoma of the thyroid:Initial presentation and response to therapy", Otolaryngol Head Neck Surg, 132, pp.840~844 (2005)
- Yuksel O, "The relation between pure papillary and follicular variant in papillary thyroid carcinoma", Endocr Regul, 42, pp.29~33 (2008)
- Lanier LL, "Identity of Leu-19(CD56)leukocyte differentiation antigen and neural cell adhesion molecule", J Exp Med, 169, pp.2233~2238 (1989)
- Scarpino S, "Papillary carcinoma of the thyroid:low expression of NCAM(CD56)is associated with downregulation of VEGF-D production by tumour cells", J Pathol, 212, pp.411~419 (2007)